DE60213237T2 - Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii - Google Patents

Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii Download PDF

Info

Publication number
DE60213237T2
DE60213237T2 DE60213237T DE60213237T DE60213237T2 DE 60213237 T2 DE60213237 T2 DE 60213237T2 DE 60213237 T DE60213237 T DE 60213237T DE 60213237 T DE60213237 T DE 60213237T DE 60213237 T2 DE60213237 T2 DE 60213237T2
Authority
DE
Germany
Prior art keywords
acid
biotin
carnitine
acetyl
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213237T
Other languages
German (de)
English (en)
Other versions
DE60213237D1 (de
Inventor
Sigma-Tau Ind. F. Riunite S.p.A Menotti CALVANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE60213237D1 publication Critical patent/DE60213237D1/de
Publication of DE60213237T2 publication Critical patent/DE60213237T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60213237T 2001-05-29 2002-05-24 Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii Expired - Lifetime DE60213237T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM20010029 2001-05-29
IT2001RM000294A ITRM20010294A1 (it) 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
PCT/IT2002/000338 WO2002096410A1 (en) 2001-05-29 2002-05-24 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus

Publications (2)

Publication Number Publication Date
DE60213237D1 DE60213237D1 (de) 2006-08-31
DE60213237T2 true DE60213237T2 (de) 2007-08-02

Family

ID=11455558

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213237T Expired - Lifetime DE60213237T2 (de) 2001-05-29 2002-05-24 Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii

Country Status (18)

Country Link
US (2) US20040142879A1 (https=)
EP (1) EP1399142B1 (https=)
JP (1) JP4381685B2 (https=)
KR (1) KR20040010666A (https=)
AT (1) ATE333274T1 (https=)
CA (1) CA2448244C (https=)
CY (1) CY1105403T1 (https=)
CZ (1) CZ297743B6 (https=)
DE (1) DE60213237T2 (https=)
DK (1) DK1399142T3 (https=)
ES (1) ES2268053T3 (https=)
HU (1) HUP0400060A2 (https=)
IT (1) ITRM20010294A1 (https=)
MX (1) MXPA03010921A (https=)
PL (1) PL207522B1 (https=)
PT (1) PT1399142E (https=)
SK (1) SK287832B6 (https=)
WO (1) WO2002096410A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006266A (es) * 2000-12-15 2004-06-25 Sigma Tau Ind Farmaceuti Uso de l-carnitina como agente estabilizador de proteinas.
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US8569366B2 (en) * 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
NZ579767A (en) * 2007-03-21 2012-04-27 Sigma Tau Ind Farmaceuti Acetyl L-carnitine, optionally combined with an antihypertensive drug or a statin, for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
GB201304112D0 (en) * 2013-03-07 2013-04-24 Univ Nottingham Modulation of energy expenditure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes

Also Published As

Publication number Publication date
JP4381685B2 (ja) 2009-12-09
ITRM20010294A0 (it) 2001-05-29
MXPA03010921A (es) 2004-02-27
CY1105403T1 (el) 2010-04-28
EP1399142A1 (en) 2004-03-24
CA2448244C (en) 2010-11-02
HUP0400060A2 (hu) 2004-04-28
CZ297743B6 (cs) 2007-03-21
US8053472B2 (en) 2011-11-08
PL367630A1 (en) 2005-03-07
PT1399142E (pt) 2006-10-31
PL207522B1 (pl) 2010-12-31
ATE333274T1 (de) 2006-08-15
US20040142879A1 (en) 2004-07-22
KR20040010666A (ko) 2004-01-31
DK1399142T3 (da) 2006-10-30
CA2448244A1 (en) 2002-12-05
US20080269307A1 (en) 2008-10-30
JP2004532866A (ja) 2004-10-28
CZ20033221A3 (cs) 2004-06-16
DE60213237D1 (de) 2006-08-31
ES2268053T3 (es) 2007-03-16
WO2002096410A1 (en) 2002-12-05
ITRM20010294A1 (it) 2002-11-29
SK287832B6 (sk) 2011-11-04
SK15852003A3 (sk) 2004-04-06
EP1399142B1 (en) 2006-07-19

Similar Documents

Publication Publication Date Title
DE69624699T2 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
DE69629273T2 (de) Zusammensetzungen enthaltend Propionyl-L-Carnitine und Hydroxyzitronensäure oder Pantothensäure
DE69910559T2 (de) Neue fettanaloge zur behandlung der fettleibigkeit
DE60130023T2 (de) Behandlung der nebenwirkungen von statinen
DE69828881T2 (de) Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen
DE69612755T2 (de) Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen
DE60214849T2 (de) Chromium/biotin behandlung von dyslipidämie
DE69826674T2 (de) Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend
DE69029693T2 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
DE3200016C2 (https=)
DE60213237T2 (de) Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii
DE2335215A1 (de) Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung
DE60207442T2 (de) VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION
DE60103835T2 (de) Chelate zur Behandlung von Helicobacter pylori Infektionen
DE69315162T2 (de) Verwendung von L-Carnitine und Acyl-L-Carnitinen zur Behandlung von Patienten die an AIDS-verwandten Syndromen leiden und von asymptomatischen HIV-seropositiven Patienten
DE2932747A1 (de) Arzneimittel zur behandlung von auf dopaminmangel beruhenden erkrankungen des zentralnervensystems
DE3035494A1 (de) Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels
DE69907387T2 (de) Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von refraktärer Vasculitis.
DE2335216A1 (de) Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung
DE69407684T2 (de) Verwendung von L-Carnitine oder Acyl-L-Carnitinen und Valproat zur Behandlung von Anfallserkrankungen
DE2712777A1 (de) Arzneimittel zur foerderung der proteinsynthese und zur konservierung des stickstoffs im koerper
DE68905424T2 (de) Alpha-glucosidaseinhibitor zur foerderung der calciumabsorption.
DE69018022T2 (de) Magnesiumcitrat als Diätzusatzmittel.
DE69936190T2 (de) Verwendung von itakonsäure zur regulierung des glykolytischen stoffwechsels
DE3936319C2 (https=)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition